Global Hospital Acquired Infection Control Market Size (2024 - 2029)

Hospital Acquired Infection Control Market Analysis

The Global Hospital Acquired Infection Control Market size is estimated at USD 4.26 billion in 2024, and is expected to reach USD 5.18 billion by 2029, growing at a CAGR of 3.97% during the forecast period (2024-2029).

The COVID-19 pandemic underlined the critical necessity of hand hygiene and the use of conventional infection control methods, as the World Health Organization and the Centers for Disease Control and Prevention (CDC) recommended, in reducing the number of hospital-acquired infections. Additionally, the article titled "Prevention of hospital-acquired infections: A construct during Covid-19 pandemic" published in September 2021, reported that in the Bihar state of India, data was collated from January 2019 to December 2020, catheter-associated urinary tract infections (CAUTI) rates were reduced by 28.01%; the central-line-associated bloodstream infections (CLABSI) rates declined by 37.61%; the surgical site infections (SSIs) rates were reduced by 62.39%, while the highest ventilator-associated pneumonia (VAP) rates were reported in November 2019. Thus, due to widespread precautions against COVID-19 to control infection, HAI was also reduced. Although to maintain the proper hygienic conditions and prevent infection, control measures were stringently followed. Thus, COVID-19 had a significant impact on the growth of the market.

Specific factors driving the market's growth include increased hospital stays due to chronic diseases and surgeries; a rise in the incidences of different types of hospital-acquired infections; and innovative technologies implemented in devices that control infection.

Hospital-acquired infections are usually caused by pathogens, which spread quickly in the body. Due to the patients' weak immune systems and poor conditions in a hospital, infections spread faster than chronic infections. According to the Centers for Disease Control and Prevention, Healthcare Associated Infection Progress Report 2020, there were nearly 18,416 surgical site infections reported in 2020 in the United States. It also reported that out of this 6.094 infections were during colon surgery and 2,173 occurred during hip arthroplasty. Such a high rate of surgical site infection creates the need for products to control HAIs and thus propels the growth of the market.

The launch of products by market players around the globe is also contributing to the growth of the market. For instance, in May 2020, Esco launched the Esco CelCulture CO2 Incubator with High Heat Sterilization (CCL-HHS). This new product adopts a 180°C dry heat sterilization system, proven effective in killing normally resistant fungi, bacterial spores, and vegetative cells that may contaminate the workspace. Such launches are expected to propel the growth of the market.

Furthermore, in November 2021, PURioLABS developed PURitALL, a high-level, portable disinfection cabinet designed to destroy infection microbes on high-touch equipment and supplies at the point of service and to prevent healthcare-associated infections (HAIs). Such launches drive the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, a lack of awareness regarding hospital-acquired infections and stringent regulatory requirements may hinder the growth of the market.

Hospital Acquired Infection Control Industry Segmentation

As per the scope of the report, hospital-acquired infections are also nosocomial infections developed in hospitals and other healthcare facilities. These infections can occur up to 48 hours after hospital admission, up to three days after discharge, up to 30 days after an operation, or in a healthcare facility when the patient was admitted for reasons other than an infection. The Hospital Acquired Infection Control Market is segmented by Product (Sterilant, Disinfectants, and Other Products), Indication (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, and Other Indications), End User (Hospitals and Intensive Care Units, Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers the value (USD million) for the above segments.